I'm sure the Vical CEO and others have read this bird flu news release today. "Food and Drug Administration officals said the Sanofi Aventis SA bird flu vaccine could play an important role despite it's limited effectiveness." ("better than nothing said Dr. Jack Stapleton of the University of Iowa Hospital")Chuckle. In a clinical trial, the two-shot series appears to provide protection to just 45% of adults who received the highest dose. I'm sure the FDA's chief of biologic products, Dr. Jesse Goodman, has heard of Vical's exciting early vaccine data. Right, Vj?
I'll bet that Sanofi Aventis would love to buy Vical for $20 a share right today! Right Vj? I believe it's time for someone to push ahead or get out of the way! Right, Vj?
we know that vaxfectin pushed current fluzone from sanofi a lot. if I see that 45% rate I propose to start a fluzone+vaxfectin trial. maybe someone can propose to vical and/or sanofi. actually it would be a shame if they dont think about it (as they already partner on fgf1) regs